BMS Reports P-II (AXIOMATIC-SSP) Study Results of Milvexian for Recurrent Symptomatic Ischemic Stroke
Shots:
- The P-II (AXIOMATIC-SSP) study evaluated milvexian (FXIa inhibitor) vs PBO in a ratio (2:1) in 2366 patients with new symptomatic ischemic stroke or new covert brain infarction who received aspirin & clopidogrel, following an acute ischemic stroke or TIA
- The results showed a 30% relative risk reduction in recurrent symptomatic ischemic strokes in patients who received 25/50/100mg, BID & a dose-response was not observed, no fatal bleeding with no increase in symptomatic intracranial hemorrhage who received 21 days of dual antiplatelet therapy, followed by single antiplatelet therapy
- The rate of major bleeding for 25mg, qd & BID was similar to PBO. The company is expected to initiate the P-III study in 2023
Ref: Businesswire | Image: BMS
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.